HexaBio

HexaBio is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics. The company leverages its proprietary Hexa-circRNA platform to design RNA molecules that are more stable and less immunogenic than traditional linear mRNA. This technology allows for prolonged protein expression, which is critical for treating chronic diseases and improving vaccine efficacy. HexaBio's current pipeline includes programs in oncology, infectious diseases, and protein replacement therapies. The company is headquartered in Singapore with significant research and development operations in China. HexaBio aims to translate its cutting-edge RNA engineering into transformative medicines for patients worldwide.